Two 13-mer snake venom peptides differing by a single leucine/phenylalanine substitution showed dual anticancer and antibacterial activity, with phenylalanine conferring significantly stronger effects against osteosarcoma.
1 amino acidleucine→phenylalanine substitution dramatically enhanced anticancer and antibacterial potency
What the researchers found
Both p-AppK and p-Acl showed dual antibacterial (including MDR strains) and anticancer activity without hemolysis. The leucine→phenylalanine substitution in p-Acl significantly enhanced activity, particularly against osteosarcoma (HOS, MG63) cells.
Why it matters
A single amino acid change dramatically altering drug properties demonstrates how natural peptide variation can be leveraged for drug design. The dual cancer/infection-fighting activity without blood cell toxicity makes these promising therapeutic candidates.
The numbers in context
Single Leu/Phe substitution; one peptide primarily antibacterial, the other primarily anticancer.
How the study worked
Peptide synthesis and characterization. Antibacterial MIC testing against Gram-positive and Gram-negative bacteria including MDR strains. Anticancer cytotoxicity against solid and liquid tumors. Hemolysis assays. Molecular dynamics simulations for mechanism. DNA-intercalating dye uptake for membrane permeability.
Who was studied
Two synthetic 13-mer venom-derived peptides tested against bacteria and cancer cells
What this study cannot tell us
In vitro study only — no animal model testing. The relationship between membrane disruption in vitro and therapeutic potential in vivo is complex. Selectivity between cancer and normal cells beyond red blood cells not fully characterized.
How to read the evidence
Thorough in vitro characterization with computational mechanistic support. Early drug discovery stage without animal testing.
When this study was published
Published in 2021. Venom-derived dual-action peptides continue to be explored for antimicrobial and anticancer applications.
The bigger picture
Snake venom continues to be a treasure trove of bioactive peptides. Understanding how single amino acid changes fine-tune activity provides a powerful design principle for creating new antibiotics and anticancer agents from natural templates.
Questions still open
- Would p-Acl show anti-osteosarcoma efficacy in animal models?
- Can this single-substitution optimization approach be applied to other venom-derived peptides?
- What determines the selectivity between cancer/bacterial membranes and normal cell membranes?
Common questions
How do these snake venom peptides kill cancer and bacteria?
Could a single amino acid change really make that much difference?
Read the original research
Lessons from a Single Amino Acid Substitution: Anticancer and Antibacterial Properties of Two Phospholipase A2-Derived Peptides.
Current issues in molecular biology, 44(1), 46-62
Citation
Almeida, José R; Mendes, Bruno; Lancellotti, Marcelo; Franchi, Gilberto C; Passos, Óscar; Ramos, Maria J; Fernandes, Pedro A; Alves, Cláudia; Vale, Nuno; Gomes, Paula; da Silva, Saulo L. (2021). Lessons from a Single Amino Acid Substitution: Anticancer and Antibacterial Properties of Two Phospholipase A2-Derived Peptides.. Current issues in molecular biology, 44(1), 46-62. https://doi.org/10.3390/cimb44010004